Oncotarget: MEK is a promising target in the basal subtype of bladder cancer

“The @Oncotarget authors demonstrate that MEK inhibitors are a promising targeted therapy for the basal subtype of bladder cancer, and their data indicate that drug screening of 3D cultures provides an important resource for hypothesis generation”

Read more

Mount Sinai Experts Address the Biological Causes of Racial Disparities in Prostate Cancer

African Americans have higher rates of prostate cancer and are more likely to die from the disease than other groups in the United States, likely due to socioeconomic factors, healthcare access problems, and tumor biology.

Read more

Model helps predict which patients will benefit most from PSMA PET scan

A new study led by researchers at the UCLA Jonsson Comprehensive Cancer Center helps identify which patients with prostate cancer will benefit most from the use of prostate-specific membrane antigen PET imaging, PSMA PET, a novel imaging technique that recently was approved by the U.S. Food and Drug Administration.

Read more